-+ 0.00%
-+ 0.00%
-+ 0.00%

Berenberg Trims Fresenius Medical Care Estimates, Price Target on FY27 Headwinds; Hold Rating Kept

MT Newswires·11/18/2026 07:01:19
Listen to the news
07:01 AM EST, 11/18/2026 (MT Newswires) -- Berenberg lowered its estimates and price target for Fresenius Medical Care (FME.F), as analysts flagged 2027 headwinds following the company's third-quarter 2026 report. "FMC reported Q3 adjusted EBIT of EUR545m, c5% ahead of consensus, supported by higher Medicare outlier payments for higher-acuity patients. Management expects this benefit to be temporary, as the Centers for Medicare & Medicaid Services (CMS) has raised the outlier threshold for 2027," analysts said in a Wednesday note. "More significantly, FMC indicated a EUR300m-350m 2027 headwind from the expiry of the Transitional Drug Add-on Payment Adjustment (TDAPA), c15% of our FY26E EBIT estimate and larger than we expected." The research firm also noted volume-related headwinds for the German healthcare company, reflecting the continued impact of earlier patient losses, with management not expecting an improvement until the second half of 2027. "A recovery in FMC's referrals alone would therefore not deliver the 2%-plus growth that its medium-term targets assume," the note said. As such, Berenberg reduced its sales, EBIT and EPS projections for 2026 to 2028. The price target was also trimmed to 37 euros from 42 euros, with the stock's hold rating unchanged.